English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
 Local TagsRelease HistoryDetailsSummary
  How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression

Bschor, T., Berghöfer, A., Ströhle, A., Kunz, D., Adli, M., Müller-Oerlinghausen, B., et al. (2002). How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. Journal of Clinical Psychopharmacology, 22(4), 427-430.

Item is

 

show all hide all

Basic

show hide
Item Permalink: https://hdl.handle.net/11858/00-001M-0000-000E-A1A5-C Version Permalink: https://hdl.handle.net/11858/00-001M-0000-000E-A1A6-A
Genre: Journal Article
Alternative Title : J. Clin. Psychopharmacol.

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Bschor, Tom1, Author
Berghöfer, Anne1, Author
Ströhle, Andreas1, Author
Kunz, Dieter1, Author
Adli, Mazda1, Author
Müller-Oerlinghausen, Bruno1, Author
Bauer, Michael1, Author
Affiliations:
1Max Planck Institute of Psychiatry, Max Planck Society, ou_1607137              

Content

show
hide
Free keywords: -
 Abstract: There is compelling evidence from placebo-controlled studies that lithium augmentation is an effective strategy in the acute and continuation treatment of refractory unipolar major depression. Authors prospectively investigated the 1-year outcome of 22 subjects diagnosed with unipolar major depression who had participated in a 4-month placebo-controlled, double- blind continuation study of lithium augmentation without relapse. At the end of the double-blind phase, the blinded medication (lithium in 14 patients, placebo in 8 patients) was tapered off over a 1-week period, while the antidepressant was continued at the same dosage for another 4 weeks. Subsequently, the antidepressant was gradually discontinued over a 4-week period. Clinical status was assessed at regular follow-up visits. During the open 6-month follow-up period, seven subjects suffered an affective recurrence, five of whom had received lithium during the placebo-controlled, double-blind phase of the study. Study data suggest that active medication should be maintained for at least 1 year after successful lithium augmentation in patients with unipolar major depressive disorder

Details

show
hide
Language(s): eng - English
 Dates: 2002-08
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 4115
ISI: 000177104100015
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Journal of Clinical Psychopharmacology
  Alternative Title : J. Clin. Psychopharmacol.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 22 (4) Sequence Number: - Start / End Page: 427 - 430 Identifier: ISSN: 0271-0749